Zevra Therapeutics is trading 7.22% lower at $10.28 in pre-market; no clear company-specific announcement for October 8, 2026, was identified.
- The latest company release located was October 2 and concerned four-year real-world MIPLYFFA data.
- The decline comes amid a weaker market backdrop and concerns about elevated Treasury yields; supplied index moves are less than 0.5% lower. This may contribute, but available evidence does not establish it as the direct cause.